Journal of thrombosis and haemostasis : JTH
-
J. Thromb. Haemost. · Apr 2013
Multicenter Study Clinical TrialEnhancing the pharmacokinetic properties of recombinant factor VIII: first-in-human trial of glycoPEGylated recombinant factor VIII in patients with hemophilia A.
N8-GP is a recombinant factor VIII (FVIII) with a site-directed glycoPEGylation for the purpose of half-life prolongation. ⋯ A single dose of up to 75 U kg(-1) N8-GP was well tolerated in patients with hemophilia A, with no safety concerns. N8-GP had a prolonged half-life, and FVIII:C activity remained at > 1% for longer than the patient's previous product. These results indicate that N8-GP has the potential to reduce dosing frequency during prophylaxis.
-
J. Thromb. Haemost. · Apr 2013
Multicenter StudyHestia criteria can safely select patients with pulmonary embolism for outpatient treatment irrespective of right ventricular function.
There has been debate over how patients with pulmonary embolism (PE) can be safely selected for outpatient treatment. ⋯ Clinical criteria, such as the Hestia criteria, could be helpful in selecting patients, including those with RV dysfunction who have a low risk of adverse clinical outcome and could be candidates for outpatient treatment.